Results 51 to 60 of about 10,879 (228)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +1 more source

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study

Balkan Medical Journal, 2023
Background: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection.
Ayşe Serra Artan, Şafak Mirioğlu, Zulal İstemihan, Elif Aksoy, Ahmet Burak Dirim, Bilger Çavuş, Özgür Akın Oto, Aslı Çifçibaşı-Örmeci, Fatih Beşışık, Yaşar Çalışkan, Savaş Öztürk, Halil Yazıcı, Sabahattin Kaymakoğlu, Aydın Türkmen   +13 more
doaj   +1 more source

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]

, 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N, Bhattacharya, Debika, Dixit, Ram, Dixit, Vivek, Dong, Tien S, Han, Steven B, Jackson, Samuel, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +9 more
core   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Gastroenterology, 2015
BACKGROUND & AIMS There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir,
M. Charlton, G. Everson, S. Flamm, Princy N. Kumar, C. Landis, Robert S. Brown, M. Fried, N. Terrault, J. O’Leary, H. Vargas, A. Kuo, E. Schiff, M. Sulkowski, R. Gilroy, K. Watt, K. Brown, P. Kwo, S. Pungpapong, K. Korenblat, A. Muir, L. Teperman, R. Fontana, J. Denning, S. Arterburn, H. Dvory‐Sobol, T. Brandt-Sarif, P. Pang, J. Mchutchison, K. Reddy, N. Afdhal, M. Fried, K. Kowdley, N. Terrault, S. Flamm, J. Lake, G. Everson, M. Sulkowski, M. Curry, R. Reddy, H. Vargas, A. Muir, A. Zaman, R. Fontana, J. O’Leary, O. Shaikh, K. Korenblat, R. Stravitz, K. Watt, N. Menon, J. Bredfeldt, Carlos Romero‐Marrero   +50 more
semanticscholar   +1 more source

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Hepatology, 2019
For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected
K. Schwarz, P. Rosenthal, K. Murray, J. Honegger, W. Hardikar, R. Hague, N. Mittal, B. Massetto, D. Brainard, C. Hsueh, J. Shao, Bandita Parhy, M. Narkewicz, Girish S Rao, S. Whitworth, S. Bansal, W. Balistreri   +16 more
semanticscholar   +1 more source

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia, Romano, Antonietta, Russo, Francesco Paolo   +2 more
core   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia, Russo, Francesco Paolo, Zanetto, A   +2 more
core   +1 more source

Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement

BioMed Research International, 2022
The manuscript mainly aimed at providing clues on improving the innate immunity of coronavirus patients and safeguarding them from both new mutant strains and black fungus infections. Coronavirus is readily mutating from one variant to another. Among the
S. Saha, G. Yeom, S. B. Nimse, D. Pal
semanticscholar   +1 more source

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

Viruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche, Audrey Coilly, Anne-Marie Roque-Afonso, Didier Samuel   +3 more
doaj   +1 more source